Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. Diabetes: Senseonics raises $20M for continuous glucose monitoring implant
Senseonics said it raised $20 million it plans to put toward pivotal trials of its fully implantable blood glucose monitor for Type I and Type II diabetics, tapping a former Abbott and LifeScan executive to lead its sales & marketing efforts.
Current investors Anthem Capital, Delphi Ventures, Greenspring Associates, Healthcare Ventures, New Enterprise Associates and other “strategic partners” participated in the round, according to a press release. Read more
2. FDA warns Steris Isomedix on QA, data manipulation issues
Steris’s Isomedix division is in the FDA’s hotseat after inspectors turned up incidents in which employees faked data on testing for medical devices.
The FDA this week unveiled a warning letter in which investigators chided Steris for failing to protect against data manipulation and for subsequently mishandling the incidents. Read more
1. Medtronic mum on potential Smith & Nephew buy
Medtronic is keeping its cards close to the vest regarding a potential acquisition of Smith & Nephew, refusing to comment today on speculation about the deal at its investor conference in New York.
“I did want to acknowledge the various speculative media reports that have been circulating over the past few days regarding a potential acquisition,” vice president of investor relations Jeff Warren said this morning. “Consistent with our long-standing practice, we do not comment on market or media speculation regarding our business or regarding potential mergers and acquisitions. I wanted to address this up front, as we know this is on many of your minds, but we will not be entertaining any questions on these or any other reports of a similar nature.” Read more
